ROLE OF MOMORDICA CHARANTIA IN GLYCEMIC CONTROL AND METABOLIC REGULATION

Momordica charantia (bitter melon), a nutraceutical-rich medicinal plant of the Cucurbitaceae family, is gaining global attention as a multi-target therapeutic candidate for diabetes and metabolic disorders. This review presents a concept-driven and mechanistically enriched synthesis of its phytochemical architecture, molecular mechanisms of glycemic regulation, and systemic metabolic effects. The plant contains diverse bioactive constituents such as charantin, polypeptide-p, vicine, cucurbitane-type triterpenoids, flavonoids, and phenolic compounds, which act through synergistic and network-based interactions. Experimental and clinical evidence suggests that Momordica charantia modulates glucose homeostasis via integrated pathways, including stimulation of insulin secretion, enhancement of insulin sensitivity, activation of AMP-activated protein kinase, facilitation of GLUT4-mediated glucose uptake, and inhibition of carbohydrate-digesting enzymes. Beyond glycemic control, it demonstrates significant potential in metabolic reprogramming by improving lipid profiles, suppressing oxidative stress, and attenuating chronic inflammation. Notably, its pleiotropic pharmacological profile aligns with systems pharmacology, supporting its relevance in precision medicine. However, translational challenges persist, including variability in phytochemical composition, lack of standardized formulations, insufficient pharmacokinetic data, and limited large-scale clinical validation. Addressing these gaps through advanced analytical technologies, improved bioavailability strategies, and well-designed clinical studies is essential. Overall, Momordica charantia represents a promising, innovative, and holistic plant-based intervention for comprehensive metabolic regulation and future therapeutic development. Its integration into functional foods, nutraceutical formulations, and combination therapies may further enhance therapeutic outcomes while minimizing adverse effects and improving patient compliance in long-term metabolic disease management strategies worldwide with significant clinical implications. Future interdisciplinary research integrating omics technologies and digital health tools will accelerate translational success.